Millipore Sigma Vibrant Logo
Attenzione: Ci siamo trasferiti. Non è più possibile acquistare i prodotti Merck Millipore nel sito MerckMillipore.comPer saperne di più

OP21 Anti-Pan-Ras (Ab-1) Mouse mAb (F132-62)

OP21
Purchase on Sigma-Aldrich

Panoramica

Replacement Information

Tabella delle specifiche principali

Species ReactivityHostAntibody Type
H, M, RMMonoclonal Antibody

Products

Numero di catalogoConfezionamento Qtà/conf
OP21-100UG Fiala di plastica 100 μg
Description
OverviewRecognizes the ~21 kDa H-, K-, and N-Ras proteins including both c- and v- Ras in SW480 and Y1 cells and normal skin tissue.
Catalogue NumberOP21
Brand Family Calbiochem®
References
ReferencesRodenhuis, S. et al., 1992 Cancer Res. (Suppl) 52, 2665s.
Sidransky, D., et al., 1992 Science 256, 102.
Bos, J.L., 1988 Mutation Res. 195, 255.
Furth, M. E., et al., 1987. Oncogene 1, 47.
Kraus, M.H., et al., 1984 Proc. Natl. Acad. Sci. USA 81, 5384.
Shimizu, K., et al., 1983 Proc. Natl. Acad. Sci. USA 80, 2112.
Taparowsky, E., et al.,1983 Cell 34, 581.
Ellis, R.W., et al., 1981 Nature 292, 506.
Shih, T.Y., et al., 1980 Nature 287, 686.
Product Information
FormLiquid
FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
Positive controlSw480 or Y1 cells or normal skin tissue
Preservative≤0.1% sodium azide
Quality LevelMQ200
Applications
Key Applications Frozen Sections
Immunofluorescence
Immunoprecipitation
Not Western Blot
Paraffin Sections
Application NotesFrozen Sections (5 µg/ml)
Immunoblotting (not recommended)
Immunofluorescence (2 µg/ml)
Immunoprecipitation (4 µg/sample)
Paraffin Sections (5 µg/ml, saponin or pepsin pre-treatment required)
Application CommentsRecognizes the p21 translational products of the H-, K- and N-ras human, as well as other mammalian c- and v-ras oncogenes. Recommended for formalin-fixed and paraffin-embedded tissue sections while Anti-Pan-Ras (Ab-2) Mouse mAb (F111-85) (Cat. No. OP22) is recommended for immunoblotting. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogenrecombinant p21 Ras
Epitopewithin the N-terminus
CloneF132-62
HostMouse
IsotypeIgG2b
Species Reactivity
  • Human
  • Mouse
  • Rat
Antibody TypeMonoclonal Antibody
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Blue Ice Only
Toxicity Standard Handling
Storage +2°C to +8°C
Do not freeze Yes
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Numero di catalogo GTIN
OP21-100UG 04055977208931

Documentation

Anti-Pan-Ras (Ab-1) Mouse mAb (F132-62) Certificati d'Analisi

TitoloNumero di lotto
OP21

Riferimenti bibliografici

Panoramica delle referenze
Rodenhuis, S. et al., 1992 Cancer Res. (Suppl) 52, 2665s.
Sidransky, D., et al., 1992 Science 256, 102.
Bos, J.L., 1988 Mutation Res. 195, 255.
Furth, M. E., et al., 1987. Oncogene 1, 47.
Kraus, M.H., et al., 1984 Proc. Natl. Acad. Sci. USA 81, 5384.
Shimizu, K., et al., 1983 Proc. Natl. Acad. Sci. USA 80, 2112.
Taparowsky, E., et al.,1983 Cell 34, 581.
Ellis, R.W., et al., 1981 Nature 292, 506.
Shih, T.Y., et al., 1980 Nature 287, 686.
Scheda tecnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision02-October-2007 RFH
ApplicationFrozen Sections (5 µg/ml)
Immunoblotting (not recommended)
Immunofluorescence (2 µg/ml)
Immunoprecipitation (4 µg/sample)
Paraffin Sections (5 µg/ml, saponin or pepsin pre-treatment required)
DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with P3X63 Ag8.653 mouse myeloma cells. Recognizes the ~21 kDa N-, K-, H-, and v-ras proteins.
BackgroundThe human ras gene family consists of three identified members, H-, K- and N-ras, encoding proteins of 188-189 amino acids and 21,000 (p21) molecular weight. Human H- and K-ras are the homologues of v-H- and v-K-ras sequences originally isolated from Harvey and Kirsten strains of rat sarcoma viruses. Normal human cellular ras genes can be activated to oncogenes by mutations occurring in codons 12, 13 and 61; such mutated, activated and transforming ras genes have been identified and isolated from human tumors and cultured tumor cells. Although the expression patterns of ras proto-oncogene proteins in normal human tissues are known, similar information for activated ras oncogene encoded p21s and their relevance to human disease diagnosis and prognosis remains to be determined.
HostMouse
Immunogenrecombinant p21 Ras
Epitopewithin the N-terminus
CloneF132-62
IsotypeIgG2b
Specieshuman, mouse, rat
Positive controlSw480 or Y1 cells or normal skin tissue
FormLiquid
FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
Concentration Label Please refer to vial label for lot-specific concentration
Preservative≤0.1% sodium azide
CommentsRecognizes the p21 translational products of the H-, K- and N-ras human, as well as other mammalian c- and v-ras oncogenes. Recommended for formalin-fixed and paraffin-embedded tissue sections while Anti-Pan-Ras (Ab-2) Mouse mAb (F111-85) (Cat. No. OP22) is recommended for immunoblotting. Antibody should be titrated for optimal results in individual systems.
Storage +2°C to +8°C
Do Not Freeze Yes
Toxicity Standard Handling
ReferencesRodenhuis, S. et al., 1992 Cancer Res. (Suppl) 52, 2665s.
Sidransky, D., et al., 1992 Science 256, 102.
Bos, J.L., 1988 Mutation Res. 195, 255.
Furth, M. E., et al., 1987. Oncogene 1, 47.
Kraus, M.H., et al., 1984 Proc. Natl. Acad. Sci. USA 81, 5384.
Shimizu, K., et al., 1983 Proc. Natl. Acad. Sci. USA 80, 2112.
Taparowsky, E., et al.,1983 Cell 34, 581.
Ellis, R.W., et al., 1981 Nature 292, 506.
Shih, T.Y., et al., 1980 Nature 287, 686.